Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); Five Below, Inc. (NASDAQ: FIVE); Maison Solutions Inc. (NASDAQ: MSS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf
By:
Grabar Law Office via
GlobeNewswire
November 14, 2025 at 09:26 AM EST
PHILADELPHIA , Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avantor, Inc. (NYSE: AVTR): Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE: AVTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024 and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/avantor-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. WHY? As alleged in a recently filed underlying securities fraud class action complaint, Avantor, Inc. (NYSE: AVTR), through certain of its officers, made materially false and misleading statements materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. WHAT YOU CAN DO NOW: If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/avantor-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AVTR #Avantor Five Below, Inc. (NASDAQ: FIVE) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Five Below Inc. (NASDAQ: FIVE) as securities fraud class action complaint allegations have survived a motion to dismiss. Current Five Below, Inc. (NASDAQ: FIVE) shareholders who have held Five Below shares since prior to December 1, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more at https://grabarlaw.com/the-latest/five-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. On August 25, 2025, key allegations of the underlying class action survived defendants’ motion to dismiss the complaint. The court determined that: “Plaintiffs plausibly allege that . . . Five Below was having serious issues executing on their trend-right strategy and stocking trending items in stores.” Moreover, certain statements regarding “the extent and cause of shrink are material to investors, misleading by omission, and thus actionable.” What You Can Do Now: If you have held Five Below (NASDAQ: FIVE) shares since prior to December 1, 2022, and would like to learn more at no cost to you, please visit https://grabarlaw.com/the-latest/five-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. You can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to you whatsoever. $FIVE #FiveBelow Maison Solutions Inc. (NASDAQ: MSS) - Securities Fraud Class Action Survives Motion to Dismiss and is Now Stayed Pending Attempts to Settle: Grabar Law Office is investigating claims on behalf of shareholders of Maison Solutions Inc. (NASDAQ: MSS) as an underlying securities fraud class action has survived a motion to dismiss the complaint and is now stayed pending attempts to settle the case. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you are a current Maison Solutions Inc. (NASDAQ: MSS) shareholder who purchased Maison shares on or shortly after its October 5, 2023 IPO and still hold shares today, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/maison-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call us at 267-507-6085 On March 31, 2025, material portions of the underlying complaint survived a motion to dismiss. On October 28, 2025, the court Ordered a stay in the class action litigation pending the parties attempts to reach settlement. WHAT YOU CAN DO NOW: If you purchased Maison Solutions Inc. (NASDAQ: MSS) on or shortly after its October 5, 2023 IPO and still hold shares today, you are encouraged visit https://grabarlaw.com/the-latest/maison-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Maison $MSS Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares prior to March 29, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/unicycive-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. WHY: As alleged in a recently filed federal securities fraud class action complaint, Unicycive Therapeutics, Inc. (NASDAQ: UNCY), through certain of its officers, made false statements and/or concealed that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application's regulatory prospects were likewise overstated; and (iii) as a result, defendants' public statements were materially false and misleading when made. WHAT YOU CAN DO NOW: If you purchased Unicycive Therapeutics, Inc. (NASDAQ: UNCY), shares prior to March 29, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/unicycive-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $UNCY #Unicycive Attorney Advertising Disclaimer Contact:
More NewsView More
Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift ↗
Today 17:19 EST
Via MarketBeat
Tickers
RKLB
Via MarketBeat
Via MarketBeat
Tickers
KRKNF
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
